Antibiotic treatment of CF lung disease: From bench to bedside

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Bals, Robert ^a   Hubert, Dominique ^b   Tümmler, Burkhard ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b Assistance Publique des Hôpitaux de Paris ^*  (France)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antimicrobial treatment; Drug development; Microbiome; Susceptibility testing

Indexed keywords

ADHESIN; ALPHA 1 ANTITRYPSIN; AMIKACINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ARIKACE; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; CXA 101; DORNASE ALFA; DOXYCYCLINE; FUSIDATE SODIUM; LEVOFLOXACIN; LINEZOLID; NUCLEIC ACID; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEMOCILLIN; TOBRAMYCIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TRIMETHOPRIM; UNCLASSIFIED DRUG; VITAMIN D;

ACHROMOBACTER XYLOSOXIDANS; ACTINOMYCES; ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL CELL; BACTERIOLOGY; BACTERIOLYSIS; BACTERIOPHAGE; BIOFILM; BURKHOLDERIA; BURKHOLDERIA CEPACIA INFECTION; CALCIUM HOMEOSTASIS; CLONAL VARIATION; COLONY FORMING UNIT; CONFOCAL LASER MICROSCOPY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DNA SEQUENCE; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEALTH CARE QUALITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; LIFESTYLE; LOWER RESPIRATORY TRACT; LUNG FUNCTION; LUNG INFECTION; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOME; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; NASAL LAVAGE; NEBULIZATION; NEPHROTOXICITY; PLANKTON; PREVOTELLA; PROPIONIBACTERIUM; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RALSTONIA; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SAMPLING; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; THROAT CULTURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT; VEILLONELLA;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG DESIGN; HUMANS; PNEUMONIA, BACTERIAL;

EID: 79958115044     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60019-2     Document Type: Article

References (51)

1. Dodge JA, Lewis PA, Stanton M, Wilsher J Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007, 29:522-526.
2. O'Sullivan BP, Freedman SD Cystic fibrosis. Lancet 2009, 373:1891-1904.
3. Gilligan PH Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991, 4:35-51.
4. Lipuma JJ The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010, 23:299-323.
5. Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 2008, 3:e2908.
6. Sibley CD, Parkins MD, Rabin HR, Surette MG The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig Drugs 2009, 10:787-794.
7. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 177:995-1001.
8. Carruthers J, Wilson JM, Chamberlain J, et al. Acceptability of the cytopipette in screening for cervical cancer. Br J Prev Soc Med 1975, 29:239-248.
9. Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2010, 48:78-86.
10. Mainz JG, Naehrlich L, Schien M, et al. Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax 2009, 64:535-540.
11. Besier S, Zander J, Kahl BC, Kraiczy P, Brade V, Wichelhaus TA The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 2008, 52:2183-2189.
12. Mena A, Smith EE, Burns JL, et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008, 190:7910-7917.
13. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009, 44:547-558.
14. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771-1776.
15. Musken M, Di FS, Romling U, Haussier S A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc 2010, 5:1460-1469.
16. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005, 365:573-578.
17. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180:802-808.
18. Hubert D, Le Roux E, Lavrut T, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009, 53:3650-3656.
19. Hubert D, Leroy S, Nove-Josserand R, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009, 8:332-337.
20. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
21. Treggiari M, Retsch-Bogart GZ, Mayer-Hamblett N, et al. Early anti-Pseudomonal infection in children with CF: study population and conduct of the "EPIC" clinical trial. Pediatr Pulmonol Suppl 2009, S32:316-317.
22. Doe SJ, McSorley A, Isalska B, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010, 9:104-109.
23. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
24. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42:307-313.
25. Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res 2010, 27:151-160.
26. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009, 53:3847-3854.
27. Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS ONE 2009, 4:e5724.
28. Geller DE Aerosol antibiotics in cystic fibrosis. Respir Care 2009, 54:658-670.
29. King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010, 54:143-148.
30. Livermore DM, Mushtaq S, Ge Y, Warner M Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009, 34:402-406.
31. Bumann D Has nature already identified all useful antibacterial targets?. Curr Opin Microbiol 2008, 11:387-392.
32. Becker D, Selbach M, Rollenhagen C, et al. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 2006, 440:303-307.
33. Chemani C, Imberty A, de Bentzmann S, et al. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect Immun 2009, 77:2065-2075.
34. Lory S, Merighi M, Hyodo M Multiple activities of c-di-GMP in Pseudomonas aeruginosa. Nucleic Acids Symp Ser (Oxf) 2009, 53:51-52.
35. Bjarnsholt T, Givskov M Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 2007, 362:1213-1222.
36. Yang L, Rybtke MT, Jakobsen TH, et al. Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitors. Antimicrob Agents Chemother 2009, 53:2432-2443.
37. Tateda K, Ishii Y, Kimura S, Horikawa M, Miyairi S, Yamaguchi K Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery?. J Infect Chemother 2007, 13:357-367.
38. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van DC Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001, 45:1930-1933.
39. Beringer P The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001, 7:434-440.
40. Kent L, Bradley JM, France M, et al. Temocillin in cystic fibrosis: a retrospective pilot study. J Cyst Fibros 2008, 7:551-554.
41. Thiel K Old dogma, new tricks - 21st Century phage therapy. Nat Biotechnol 2004, 22:31-36.
42. Krylov VN Phagotherapy in terms of bacteriophage genetics: hopes, perspectives, safety, limitations. Genetika 2001, 37:869-887.
43. Kanzler H, Barrat FJ, Hessel EM, Coffman RL Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-559.
44. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13:1423-1430.
45. Griese M, Latzin P, Kappler M, et al. alphal-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007, 29:240-250.
46. Holick MF Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
47. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
48. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros 2007, 6:403-410.
49. Clement CG, Evans SE, Evans CM, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008, 177:1322-1330.
50. Evans SE, Scott BL, Clement CG, et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2010, 42:40-50.
51. Katz ML, Mueller LV, Polyakov M, Weinstock SF Where have all the antibiotic patents gone?. Nat Biotechnol 2006, 24:1529-1531.